Rami Manochakian, Associate Professor and Thoracic Medical Oncologist at Mayo Clinic, shared a post on X:
“OncoAlert – Hot off the press. Just published NEJM.
In conjunction with presentation ESMO.
Results of phase 1 trial of:
Setidegrasib in patients with KRAS/G12D mutant non-small cell Lung Cancer and Pancreas Cancer.
- Adverse Events (AEs) ≥ 3: 42%
- Response Rate (RR): 36% in NSCLC , 24% in Pancreatic Cancer .
Title: Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
Authores: Wungki Park, Anup Kasi, Alexander I. Spira, Luis Paz-Ares Rodríguez, Benjamin O. Herzberg, Meredith S. Pelster, Anthony W. Tolcher, Yasutoshi Kuboki, Shigehisa Kitano, Hirokazu Shoji, Judy S. Wang, Jordan D. Berlin, Antoine Hollebecque, Patricia LoRusso, Christos Fountzilas, Philippe A. Cassier, Tomohiro Nishina, Daisuke Sakai, Chiaki Inagaki, Daniel Morgensztern, Makoto Ueno, Minkyu Jung, Sang-We Kim, Pasi A. Jänne, Antoine Italiano, Benoît You, T Macarulla, Hisaki Fujii, Aditya Shetty, Ying Lu, Daniel Cui, Shilpa Kadam, Stanley C. Gill, Junko Toyoshima, Takeshi Saito, and Jonathan W. Goldman.”
Other articles featuring Rami Manochakian on OncoDaily.